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ABSTRACT 
Background:  Only a subset of patients with excessive alcohol use develop alcoholic liver disease (ALD); 
though the exact mechanism is not completely understood.  Once ingested, alcohol is metabolized by 2 
key oxidative enzymes, alcohol (ADH) and aldehyde dehydrogenase (ALDH).  There are 2 major ALDH 
isoforms, cytosolic and mitochondrial, encoded by the aldehyde ALDH1 and ALDH2 genes, respectively. 
The ALDH2 gene was hypothesized to alter genetic susceptibility to alcohol dependence and alcohol-
induced liver diseases.  The aim of this study is to determine the association between aldehyde 
dehydrogenase 2 (rs671) glu504lys polymorphism and ALD.   
Methods:  ALDH2 genotype was performed in 535 healthy controls and 281 patients with ALD. 
Results:  The prevalence of the common form of the SNP rs671, 504glu (glu/glu) was significantly higher 
in patients with ALD (95.4%) compared to that of controls (73.7%, p<0.0001).  Among controls, 23.7% 
had heterozygous (glu/lys) genotype when compared to 4.6% in those with ALD (OR 0.16, 95%CI 0.09-
0.28).  The allele frequency for 504lys allele in patients with ALD was 2.3%; compared to 14.5% in 
healthy controls (OR 0.13, 95%CI 0.07-0.24). 
Conclusions:  Patients with ALDH2 504lys variant were less associated with ALD compared to those with 
ALDH2 504glu using both genotypic and allelic analyses.     
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INTRODUCTION 
Excessive alcohol drinking is one of the most significant risk factors for health problems such as 
injuries, liver diseases, and cancer[1].  Drinking becomes excessive when it causes or elevates the risk for 
alcohol-related problems or complicates the management of other health problems.  According to the 
National Institute on Alcohol Abuse and Alcoholism (NIAAA), excessive drinking is defined as men who 
drink more than 4 standard drinks in a day (or more than 14 per week) and women who drink more than 
3 drinks in a day (or more than 7 per week)[2].   Alcoholic liver disease (ALD) is a major adverse health 
event resulting from excessive drinking.  Its pathogenesis is a multi-step process consisting of a series of 
histopathological changes[3].  More than 90% of drinkers develop alcoholic steatosis which is reversible 
upon abstinence[4].  However, if excessive alcohol use continues, the disease may progress to alcoholic 
hepatitis, advanced fibrosis, and alcoholic cirrhosis in up to 10-15% of heavy drinkers[3].  It is completely 
unknown why only a subset of excessive alcohol drinkers develops ALD.  
Once ingested, more than 90% of alcohol is eliminated via metabolic degradation in the liver into 
acetaldehyde, mainly by alcohol dehydrogenase enzyme (ADH)[5].  Acetaldehyde is subsequently 
converted by aldehyde dehydrogenases (ALDH) to acetate, which is released from the liver and 
metabolized by the heart and muscle[5]. The rate of alcohol metabolism by ADH and ALDH is critical in 
determining its toxicity because the intermediate, acetaldehyde, is potentially toxic[5].   There are 2 major 
ALDH isoforms, cytosolic and mitochondrial, encoded by the aldehyde ALDH1 and ALDH2 genes, 
respectively. The ALDH2 gene was hypothesized to alter genetic susceptibility to alcohol dependence and 
alcohol-induced liver diseases.  Between both isoforms, mitochondrial ALDH2 plays the central role in 
human acetaldehyde metabolism because of its submicromolar Km for acetaldehyde[5].  
The ALDH2 gene is polymorphic and the variants demonstrate the vital role of ALDH2 activity in 
alcohol oxidation.  A single nucleotide polymorphism (SNP) at exon 12 predicts lysine at residue 504 
instead of glutamic acid[6]. The common form of the SNP (rs671) (504glu) encodes the glu (G) allele 
(previously referred to as the ALDH2 *1 allele); the 504lys (A, formerly ALDH2 *2 and 487lys) allele 
produces a catalytically inactive isozyme and limits its activity to metabolize acetaldehyde[6, 7].  As a 
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result, subjects with the lys allele have a reduced capacity to eliminate acetaldehyde and typically have 
unpleasant side effects such as flushing, nausea, or vomiting after alcohol consumption[8, 9].  In fact, the 
peak blood acetaldehyde concentration after alcohol consumption is 6- and 19-fold higher in 
heterozygotes or homozygotes for 504lys allele than that in common allele individuals [10].  It is 
therefore plausible that those with this allele could have decreased risk of excessive alcohol usedue to 
adverse reactions from drinking, and subsequently, this allele could influence the risk of alcohol-related 
diseases such as ALD.  To address this question, we performed a single center study in a well 
characterized cohort of Chinese patients to determine the association between ALDH2 variants and ALD.  
METHODS      
Human subject cohort 
The study was performed at the Beijing 302 hospital; a large tertiary care center specialized in the 
treatment of liver diseases.  The study was conducted in accordance with the guidelines set by the 
Declaration of Helsinki. Written informed consent was obtained from each participant and the study was 
approved by the Ethics Committee of the Beijing 302 hospital.  Five hundred and thirty-five healthy men 
without history of excessive alcohol use or other causes of chronic liver diseases with normal hepatic 
panel seen at an outpatient clinic for routine health screening were enrolled.  Two hundred and eighty 
one patients with alcoholic cirrhosis and no known history of hepatitis B or C infection were recruited 
from the Center for Diagnosis and Treatment of Non-infectious Liver Disease between June 2013 and 
January 2015.  These cases were age and gender-matched to healthy controls.  Alcoholic cirrhosis patients 
had history of alcohol consumption averaging at least 80 g per day (for men) or 50 g per day (for women), 
for at least 10 years [11].  The diagnosis of cirrhosis was made by radiographic imaging or clinical 
presentation of portal hypertension such as hepatic encephalopathy, ascites or the presence of 
esophageal varices on upper gastrointestinal endoscopy with exclusion of other known causes of chronic 
liver diseases such as hepatitis B or C and autoimmune liver diseases.   
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Data and biosample collection 
All subjects completed self-administered questionnaires regarding history of alcohol 
consumption.   Demographic data, medical history, and clinical characteristics were collected.  Baseline 
laboratory tests were obtained and blood was collected from venipuncture and stored at -80oC until DNA 
extraction.    
Extraction of genomic DNA 
Genomic DNA was extracted using QIAamp DNA Blood Mini Kit (Qiagen, New York, USA).  The 
concentration of DNA was quantified by a Nanodrop 1000 UV-Vis spectrophotometer.  All PCRs were 
performed using 1µl of genomic DNA (1-10ng) in a final volume of 5 µl according to Custom Taqman® SNP 
genotyping assays kits for ALDH2 (ABI, Foster City, California, USA) with LightCycler® 480 Type II System 
(Roche, Basel, Switzerland). The forward and reverse primer sequence of ALDH2 was 5’-
TTTGGTGGCTAGAAGATGTC-3’, and 5’-CACACT CACAGTTTTCTCTT-3’, respectively.  PCR conditions were 
set as follows: 94 °C (30 seconds), 57 °C (30 seconds), 72 °C (30 seconds) for a total of 40 cycles.   
Statistical analysis 
Basic descriptive statistics, including mean, standard deviations (SD), and percentages were used.  
Chi-square test and Student’s t-test were used for comparison between groups for categorical and 
continuous variables, respectively.  A P value of <0.05 was considered as statistical significance.  All 
analyses were performed with SPSS 16.0 for Windows (SPSS Chicago, Illinois, USA).   
RESULTS 
Demographic and clinical characteristics of the study cohort  
The detailed characteristics of subjects with ALD are summarized in Table 1.  The mean age of 
patients with ALD was 49 years which was comparable to that of controls (48 years).  The average 
duration of drinking was 21.5 years with daily drinking on the average of 95 grams.   
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The prevalence of ALDH2 variants in healthy controls and patients with ALD 
We found that the prevalence of the common form of the SNP rs671, 504glu (glu/glu) was 
significantly higher in patients with ALD (95.4%) compared to that of controls (73.7%, p<0.0001).  
Among controls, 23.7% had heterozygous (glu/lys) genotype when compared to 4.6% in those with ALD 
(p<0.0001, OR 0.16, 95%CI 0.09-0.28).  None of the patients with ALD had homozygous lys/lys genotype; 
when compared to 2.6% among controls (p=0.05).  The allele frequency for 504lys allele in patients with 
ALD was 2.3%; compared to 14.5% in healthy controls (p<0.0001, OR 0.13, 95%CI 0.07-0.24, Table 2). 
Clinical characteristics of ALD patients stratified by ALDH2 variants    
We next determine the alcohol consumption history as well as clinical characteristics of ALD 
patients stratified by ALDH2 variants (Table 3).  ALD patients with heterozygous (glu/lys) genotype had 
shorter duration of drinking before the enrollment (17.3±9.3 years) than those with glu/glu genotype 
(22.5±10.6 years), though the difference was not statistical significance (p=0.09).  However, that daily 
alcohol consumption was significantly lower in patients with heterozygous genotype (50.0±28.5 vs. 
128.7±56.2 grams, p=0.001).  While most laboratory tests were comparable between both groups, ALD 
patients with heterozygous (glu/lys) genotype had lower mean corpuscular volume (90.5±8.3 vs. 
99.1±59.5 fl, p=0.04), lower total bilirubin (1.6±0.1 vs. 4.8±1.1 mg/dl, p=0.006), and lower alkaline 
phosphatase (101.6±55.9 vs. 155.2±112.4 U/L, p=0.02) than those with glu/glu genotype.      
Clinical characteristics of ALD patients with similar quantity of alcohol consumption stratified by 
ALDH2 variants    
The development of ALD depends on the quantity and quality of alcohol consumption.  As shown 
in Table 3, the quantity of alcohol consumption was significantly lower in those with heterozygous 
genotype.  To further assess clinical characteristics of ALD patients stratified by ALDH2 variants adjusting 
for the quantity of alcohol consumption, we randomly selected patients with glu/glu genotype (n=66) 
with the duration and daily alcohol consumption matched to those with glu/lys genotype (n=11, Table 4).  
We found that patients with glu/lys genotype had lower total bilirubin level (1.6±0.9 vs. 3.9±3.8 mg/dl, 
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p=0.01) and alkaline phosphatase (96.6±53.4 vs. 163.0±100.6 U/l, p=0.03) 
DISCUSSION 
The major findings in our study is that patients with ALDH2 504lys variant were less associated 
with ALD compared to those with ALDH2 504glu using both genotypic and allelic analyses.   
A single nucleotide polymorphism on ALDH2 gene affects its enzymatic activity and its ability to 
metabolize acetaldehyde into acetate after alcohol ingestion[5, 6, 12].  The lys allele plays an important 
role in regulating the ALDH2 activity, for instance, the reduction in ALDH2 activity in patients with 
heterozygous (glu/lys) genotype is more than 100-fold compared with that of glu/glu homozygotes[5, 6].  
Hepatic ALDH2 activity is almost non-detectable in heterozygous gly/lys and homozygous lys/lys 
patients[12].  Thus, the accumulation of acetaldehyde commonly occurs in patients with lys allele after 
alcohol consumption leading to vasodilation, facial flushing, tachycardia, nausea, and vomiting[8, 9].  It is 
postulated that this allele protects against excessive alcohol use or alcoholism because of unpleasant 
symptoms secondary to acetaldehyde accumulation.   Several studies demonstrated a reduced frequency 
of the lys allele in alcoholics compared with to non-alcoholics[13-15].  Individuals with the lys allele have 
a 10-fold reduction in the risk of alcohol dependence[13], drink less alcohol, and have a lower prevalence 
of binge drinking[16, 17].  In our study, we also found that ALD patients with lys allele had significantly 
lower quantity of alcohol consumption compared to those with homozygous glu/glu genotype.   
Previous studies have shown that the inactive ALDH2 504lys allele occurred mainly in Asian 
populations[5, 13].  Most alcoholics with inactive ALDH2 alleles were heterozygous while homozygous 
lys/lys was rarely found in the alcoholic subjects, although it was often observed in controls[6].  These 
findings are similar to what we observed in our study.  The allele frequency for 504lys among patients 
with ALD is around 1.0%-11.6%, depending on the population being studied[6].  In this report, the overall 
frequency of this allele in our patients is 2.3%. 
We found that patients with ALDH2 504lys are protected against alcoholic liver disease.  Our 
findings are in accordance with previous reports[6, 18, 19].  It is plausible that this is the consequence of 
the reduction in risk of alcoholism among patients carrying this allele.  However, when we carefully 
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analyzed alcohol drinking history, we found that these patients had a shorter duration (though 
notstatistocally significant) and less daily quantity of alcohol consumption when compared to those with 
ALDH2 504glu; suggesting the potential adverse effects of acetaldehyde accumulation secondary to lack 
of ALDH2 enzyme activity leading to ALD.  We cannot directly test this hypothesis given the nature of our 
study design; however, in an animal study, Aldh2-/- mice were found to have hepatic inflammation and 
fibrosis after alcohol feeding when compared to wild type counterparts [20]; supporting our human 
observation.  To further test the role of acetaldehyde-induced liver injury, we also performed additional 
analyses by randomly selecting patients with comparable alcohol consumption from those with glu/glu 
(n=66) and glu/lys (n=11) genotypes.  We did not observe the differences in the levels of aspartate (AST) 
and alanine (ALT) aminotransferases between both groups (Table 4).  However, there is a limitation 
regarding the sample size in this analysis.  Lastly, we found that ALD patients with ALDH2 504glu had 
higher level of mean corpuscular volume compared to those with ALDH2 504lys.  We believe that high 
corpuscular volume in these patients is likely due to higher quantity of alcohol consumption in this 
group[21, 22]. 
In conclusion, using both genotypic and allelic analyses, we found that the presence of the lys 
allele may be protected against ALD in a large cohort of Chinese patients.   
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Table 1.  Baseline demographic and clinical characteristics of the study cohort with ALD 
Variables ALD 
(N=281) 
Age (years) 49.4±9.8 
Alcohol consumption history 
Duration of drinking (years) 
Estimated daily alcohol intake (grams)  
Estimated lifetime alcohol consumption (kilograms) 
21.5±9.7 
94.8±55.8 
765.5±611.0 
Body mass index (kg/m2) 24.8±3.8 
White blood cells (103xcells/mm3)  5.6±4.2 
Hemoglobin (g/dl) 11.6±3.2 
Platelet counts (103xcells/mm3) 104±73 
Total Bilirubin (mg/dL) 4.1±4.5 
Aspartate aminotransferase (U/L) 97.7±103.4 
Alanine aminotransferase (U/L) 95.1±145.2 
Albumin (g/dL) 3.2±0.7 
Alkaline phosphatase (U/L) 151.8±112.4 
Gamma glutaryltransferase (U/L) 263.8±370.1 
Table 2. The prevalence of ALDH2 Glu504Lys (rs671) variants in healthy controls and patients 
with ALD  
Controls 
(N=535) 
ALD 
(N=281) 
P-value OR 95%CI 
n % n % 
Genotype distribution 
Glu/Glu 394 73.7 268 95.4 <0.0001 7.38 4.09-13.3 
Gly/Lys 127 23.7 13 4.6 <0.0001 0.16 0.09-0.28 
Lys/Lys 14 2.6 0 0 0.05 0.06 0.004-1.07 
Allele frequency 
Glu 915 85.5 549 97.7 <0.001 7.15 4.02-12.72 
Lys 155 14.5 13 2.3 <0.0001 0.13 0.07-0.24 
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Table 3.  Clinical characteristics of ALD patients stratified by ALDH2 variants 
Clinical characteristics ALDH2 Glu504Lys (rs671) 
variants 
P-value
Glu/Glu 
(N = 268) 
Glu/Lys 
(N = 13) 
Alcohol consumption history 
      Duration of drinking (years) 22.5±10.6 17.3±9.3 0.09 
      Estimated daily alcohol intake (grams)  128.7±56.2 50.0±28.5 0.001 
    Estimated lifetime alcohol consumption (kilograms) 897.1±714.9 317.9±243.8 0.0003 
Body mass index (kg/m2） 24.8±3.9 24.7±3.7 0.98 
Platelet counts (109/L) 108.8±77.3 114.5±77.8 0.72 
Mean corpuscular volume (fL) 99.1±59.5 90.5±8.3 0.04 
Alanine aminotransferase (U/L) 82.5±132.9 58.4±48.2 0.65 
Aspartate aminotransferase (U/L) 90.9±97.1 73.9±57.4 0.67 
Total bilirubin（mg/dl） 4.8±1.1 1.6±0.1 0.006 
Alkaline phosphatase (U/L) 155.2±112.4 101.6±55.9 0.02 
Gamma gluteryltransferase (U/L) 256.9±370.2 165.0±242.7 0.18 
Table 4.  Clinical characteristics of ALD patients with similar quantity of alcohol consumption 
stratified by ALDH2 variants  
Clinical characteristics ALDH2 Glu504Lys (rs671) 
variants 
P-value
Glu/Glu 
(N = 66) 
Glu/Lys 
(N = 11) 
Alcohol consumption history 
      Duration of drinking (years) 18.1±6.6 18.6±8.6 0.87 
      Estimated daily alcohol intake (grams)  56.7±16.2 44.4±21.0 0.09 
      :Estimated lifetime alcohol consumption 
(kilograms) 
359.1±129.4 294.7±174.4 0.26 
Body mass index (Kg/m2） 24.4±3.6 25.1±4.0 0.63 
Platelet counts (109/L) 112.0±74.7 121.4±78.7 0.72 
Mean corpuscular volume (fL) 95.7±13.8 90.7±8.9 0.13 
Alanine aminotransferase (U/L) 79.1±67.3 55.4±48.3 0.26 
Aspartate aminotransferase (U/L) 102.3±94.0 63.1±34.3 0.17 
Total bilirubin（mg/dl） 3.9±3.8 1.6±0.9 0.01 
Alkaline phosphatase (U/L) 163.0±100.6 96.6±53.4 0.03 
Gamma gluteryltransferase (U/L) 295.3±412.9 165.3±256.8 0.31 
